Three hospitals have sued CVS Health, alleging the company redirected $250 million in savings from the 340B Drug Pricing Program. Mount Sinai Hospital, the University of Kansas Hospital Authority, and the University of Michigan Hospitals and Health Centers filed lawsuits, claiming CVS siphoned funds meant for the hospitals. The claims, handled by law firm Frier Levitt, accuse CVS Health, CaremarkPCS Health, and others of manipulating reimbursement rates for specialty drugs.
The lawsuits describe a process where hospitals agreed to pass through third-party payments for 340B specialty drug claims, except for specific fees. However, the complaints allege that CaremarkPCS secretly paid CVS Specialty a reduced rate after claims were flagged as 340B-eligible. WellPartner, another party, then informed hospitals of the lower reimbursement amount, hiding the original higher payment. The law firm said this allowed CVS to retain the “spread” as profit.
According to the complaints, this practice diverted about $250 million between 2020 and 2025. The hospitals argue that the 340B program requires drug manufacturers to offer discounts on outpatient drugs to qualifying hospitals, which then bill payers at full price to fund care for low-income patients. The lawsuits claim CVS’s actions undermined this revenue stream.
Controversies and Broader Implications
The 340B program, established in 1992, has long faced scrutiny. Critics point to issues like hospitals misusing the program, lack of transparency in pricing, and unclear use of generated revenue. The Commonwealth Fund highlighted concerns over duplicate discounts, where drugs receive 340B prices and additional rebates through programs like Medicaid. Last year, multiple hospital groups sued to block a proposed shift of the 340B program into a rebate model.
For hospitals relying on 340B savings, the alleged diversion raises practical concerns. Reduced revenue could limit their ability to expand services for vulnerable patients. While the lawsuits focus on financial missteps, they also highlight the program’s fragility and the challenges of ensuring compliance across a complex network of pharmacies and insurers.
Experts have long debated the balance between cost control and equitable access in healthcare. The 340B program was designed to ensure that eligible hospitals could afford medications for underserved populations, but its implementation has sparked ongoing disputes over accountability. Some argue that the program’s structure invites exploitation, while others emphasize its role in subsidizing care for those who cannot afford it.
Related: Cityblock and Meridian partner to serve Illinois Medicaid populations
Recent developments in the legal setting show the growing tension between pharmaceutical companies and healthcare providers. The lawsuits against CVS Health are part of a broader trend, with similar cases emerging across the country. These disputes reflect deeper systemic issues in how drug pricing and reimbursement are managed, particularly in programs intended to serve low-income communities.
As the legal battles unfold, the focus remains on ensuring that the 340B program fulfills its intended purpose. Advocates for hospitals stress the need for clearer regulations and greater transparency in how savings are distributed. Meanwhile, industry representatives defend current practices, claiming they are necessary to maintain operational sustainability.
One area of particular interest is the role of intermediaries like CaremarkPCS and WellPartner in the reimbursement process. Their involvement has raised questions about whether they act as facilitators or whether they contribute to the financial discrepancies alleged in the lawsuits. Investigators are examining whether these entities have influenced pricing decisions in ways that benefit private interests over public health needs.
The potential impact on Medicaid populations cannot be ignored. Hospitals that rely heavily on 340B savings often serve patients who depend on Medicaid for essential care. If these savings are reduced, it could strain resources and limit access to critical treatments. Some states have already seen ripple effects from similar disputes, with hospitals reporting delays in service expansions and increased financial pressures.
The lawsuits also highlight the complexity of the healthcare supply chain. From drug manufacturers to pharmacies and insurers, each stakeholder plays a role in determining final costs. This interconnectedness makes it difficult to trace where profits are being taken and where resources are being allocated. Experts suggest that reforms may require a more holistic approach, addressing not just individual actors but the entire ecosystem of drug distribution.